Retatrutide is an unlicensed investigational triple receptor agonist (GLP-1, GIP, glucagon) with no UK marketing authorisation
Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients
Olsson Y, Hodzic K, Wass C, et al
With approximately 25 million projected GLP-1 users by 2030 up from roughly 11 million in 2025 and the behavioral evidence showing consistent, durable changes in eating patterns, the brands that adapt their packaging, portions, and nutritional profiles now will build a competitive advantage that compounds over time
In more serious cases it can cause dangerous dehydration, hypoglycaemia (particularly if you take other diabetes medications), and even organ complications in some cases, though rare